EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSONIG00000012985
Gene Symbol: LOC100534577
4 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a

Ensembl ID : ENSONIG00000003190
Gene Symbol: LOC100698622
3 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3b

Ensembl ID : ENSONIG00000000888
Gene Symbol: LOC100692877
2 Cross references
226 Possible Orthologues:

Glutamate Receptor Subunit 2a

Ensembl ID : ENSONIG00000016067
Gene Symbol: GLUR2A
3 Cross references
242 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSONIG00000001193
Gene Symbol: GRIA2B
1 Cross references
224 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSONIG00000018007
Gene Symbol: GRIN2BB
1 Cross references
250 Possible Orthologues:

Glutamate Receptor, Metabotropic 5a

Ensembl ID : ENSONIG00000004711
Gene Symbol: GRM5A
1 Cross references
211 Possible Orthologues:

Glutamate Receptor, Metabotropic 5b

Ensembl ID : ENSONIG00000005131
Gene Symbol: GRM5B
1 Cross references
214 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial

Ensembl ID : ENSONIG00000016812
Gene Symbol: LOC100711430
2 Cross references
232 Possible Orthologues:

Glutaminase Kidney Isoform, Mitochondrial

Ensembl ID : ENSONIG00000012207
Gene Symbol: LOC100706550
3 Cross references
230 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha A

Ensembl ID : ENSONIG00000004984
Gene Symbol: GSK3AA
1 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha B

Ensembl ID : ENSONIG00000039856
Gene Symbol: GSK3AB
1 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).